IL15 and vitiligo: The three emerging vitiligo therapeutic classes that are at the most advanced stage of development and are associated with the most important pathogenic pathways are the tyrosine kinase inhibitors (e.g., JAK1, JAK2, JAK3, TYK2), anti-IL15, and mutant HSP70.74, 88, 107, Table 3 shows the emerging drugs according to their pathophysiological target.